BR112023018293A2 - Acopladores de célula t multiespecíficos à base de darpin - Google Patents

Acopladores de célula t multiespecíficos à base de darpin

Info

Publication number
BR112023018293A2
BR112023018293A2 BR112023018293A BR112023018293A BR112023018293A2 BR 112023018293 A2 BR112023018293 A2 BR 112023018293A2 BR 112023018293 A BR112023018293 A BR 112023018293A BR 112023018293 A BR112023018293 A BR 112023018293A BR 112023018293 A2 BR112023018293 A2 BR 112023018293A2
Authority
BR
Brazil
Prior art keywords
proteins
darpin
nucleic acids
multispecific
specific
Prior art date
Application number
BR112023018293A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernd Schlereth
Christian Reichen
Matteo Bianchi
Nina Reschke
Sebastian Grimm
Victor Levitsky
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112023018293A2 publication Critical patent/BR112023018293A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Amplifiers (AREA)
  • Liquid Crystal Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023018293A 2021-03-09 2022-03-09 Acopladores de célula t multiespecíficos à base de darpin BR112023018293A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163158539P 2021-03-09 2021-03-09
US202163172973P 2021-04-09 2021-04-09
US202163265184P 2021-12-09 2021-12-09
PCT/IB2022/052126 WO2022190016A1 (en) 2021-03-09 2022-03-09 Novel darpin based multi-specific t-cell engagers

Publications (1)

Publication Number Publication Date
BR112023018293A2 true BR112023018293A2 (pt) 2023-10-31

Family

ID=81327872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018293A BR112023018293A2 (pt) 2021-03-09 2022-03-09 Acopladores de célula t multiespecíficos à base de darpin

Country Status (11)

Country Link
US (2) US11834504B2 (https=)
EP (1) EP4304731A1 (https=)
JP (1) JP2024509904A (https=)
KR (1) KR20230155464A (https=)
AU (1) AU2022234894A1 (https=)
BR (1) BR112023018293A2 (https=)
CA (1) CA3211381A1 (https=)
CO (1) CO2023012681A2 (https=)
IL (1) IL305677A (https=)
MX (1) MX2023010543A (https=)
WO (1) WO2022190016A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305677A (en) * 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
EP4724486A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025163082A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
BRPI0517834A (pt) 2004-11-12 2008-10-21 Bayer Schering Pharma Ag vìrus da doença de newcastle recombinante
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
WO2017040855A1 (en) * 2015-09-02 2017-03-09 Dose Medical Corporation Drug delivery implants as intraocular drug depots and methods of using same
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
RU2020135920A (ru) 2018-04-05 2022-05-05 Новартис Аг Триспецифические связывающие молекулы против форм рака и пути их применения
BR112020020604A2 (pt) * 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
CN120058958A (zh) * 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
US12441772B2 (en) 2019-06-04 2025-10-14 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
SG11202112925PA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Recombinant fap binding proteins and their use
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
CN114206943A (zh) * 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
CA3161319A1 (en) 2019-12-11 2021-06-17 Victor LEVITSKY Recombinant peptide-mhc complex binding proteins and their generation and use
KR20220113492A (ko) 2019-12-11 2022-08-12 몰리큘라 파트너스 아게 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인
KR20230006558A (ko) 2020-05-06 2023-01-10 몰리큘라 파트너스 아게 신규한 안키린 반복 결합 단백질 및 그의 용도
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
US20240279309A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
US20240052033A1 (en) 2020-12-16 2024-02-15 Molecular Partners Ag Recombinant cd3 binding proteins and their use
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
WO2022190010A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd33 engagers
IL305677A (en) * 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
EP4319883A1 (en) 2021-04-09 2024-02-14 Molecular Partners AG Novel darpin based cd70 engagers

Also Published As

Publication number Publication date
KR20230155464A (ko) 2023-11-10
CA3211381A1 (en) 2022-09-15
JP2024509904A (ja) 2024-03-05
US20240254229A1 (en) 2024-08-01
AU2022234894A9 (en) 2024-02-22
WO2022190016A1 (en) 2022-09-15
AU2022234894A1 (en) 2023-10-05
MX2023010543A (es) 2023-10-13
US20230056271A1 (en) 2023-02-23
US11834504B2 (en) 2023-12-05
IL305677A (en) 2023-11-01
EP4304731A1 (en) 2024-01-17
CO2023012681A2 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
BR112023018293A2 (pt) Acopladores de célula t multiespecíficos à base de darpin
BR112023020685A2 (pt) Acopladores de cd70 baseados em darpin
BR112022023049A2 (pt) Proteínas multiespecíficas
Raineri et al. Osteopontin binds ICOSL promoting tumor metastasis
Boyle et al. ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism
Ventelä et al. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance
Chen et al. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases
Tang et al. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial–mesenchymal transition
Lee et al. Increased SCF/c‐kit by hypoxia promotes autophagy of human placental chorionic plate‐derived mesenchymal stem cells via regulating the phosphorylation of mTOR
Chang et al. Aurora A kinase activates YAP signaling in triple-negative breast cancer
BR112021024231A2 (pt) Proteínas de ligação fap recombinantes e uso da mesma
Fang et al. Centlein mediates an interaction between C-Nap1 and Cep68 to maintain centrosome cohesion
ES2166352T3 (es) Dominio externo de c-erbb-2:gp75.
Au et al. TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis
Kwak et al. Reactive oxygen species induce Cys106-mediated anti-parallel HMGB1 dimerization that protects against DNA damage
ES2053810T3 (es) Nuevos anticuerpos quimericos.
Pott et al. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
BR112022018491A2 (pt) Marcadores de superfície celular recombinante
Behera et al. Abrus precatorius agglutinin-derived peptides induce ROS-dependent mitochondrial apoptosis through JNK and Akt/P38/P53 pathways in HeLa cells
Pellacani et al. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer
Huggins et al. Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers
Deng et al. Efficient cell chatting between embryo and uterus ensures embryo implantation
BR112021017703A8 (pt) Receptores de células t wt1 de alta avidez e usos dos mesmos
Xu et al. Transcription coactivator Cited1 acts as an inducer of trophoblast-like state from mouse embryonic stem cells through the activation of BMP signaling